Back to Search
Start Over
Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile
- Source :
- Current Opinion in Neurology, Current Opinion in Neurology, Lippincott, Williams & Wilkins, 2020, 33 (4), pp.413-421. ⟨10.1097/WCO.0000000000000833⟩, Current Opinion in Neurology, 2020, 33 (4), pp.413-421. ⟨10.1097/WCO.0000000000000833⟩, Curr Opin Neurol
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- International audience; Purpose of review Magnetic resonance spectroscopy (MRS) may play a key role for the management of patients with glioma. We highlighted the utility of MRS in the noninvasive diagnosis of gliomas with mutations in isocitrate dehydrogenase (IDH) genes, by providing an overview of the neurochemical alterations observed in different glioma subtypes, as well as during treatment and progression, both in vivo and ex vivo.Recent findings D-2-hydroxyglutarate (2HG) decrease during anticancer treatments was recently shown to be associated with altered levels of other metabolites, including lactate, glutamate and glutathione, suggesting that tumour treatment leads to a metabolic reprogramming beyond 2HG depletion. In combination with 2HG quantification, cystathionine and glycine seem to be the most promising candidates for higher specific identification of glioma subtypes and follow-up of disease progression and response to treatment.Summary The implementation of advanced MRS methods in the routine clinical practice will allow the quantification of metabolites that are not detectable with conventional methods and may enable immediate, accurate diagnosis of gliomas, which is crucial for planning optimal therapeutic strategies and follow-up examinations. The role of different metabolites as predictors of patient outcome still needs to be elucidated.
- Subjects :
- 0301 basic medicine
Magnetic Resonance Spectroscopy
treatment effect
brain metabolites
[SDV]Life Sciences [q-bio]
Article
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Neurochemical
In vivo
Glioma
glioma
Humans
Medicine
biology
Brain Neoplasms
business.industry
Glutamate receptor
Glutathione
medicine.disease
Cystathionine beta synthase
IDH mutation
Isocitrate Dehydrogenase
3. Good health
[SDV] Life Sciences [q-bio]
030104 developmental biology
Isocitrate dehydrogenase
Neurology
chemistry
Mutation
biology.protein
Cancer research
Neurology (clinical)
progression
business
030217 neurology & neurosurgery
Ex vivo
Subjects
Details
- Language :
- English
- ISSN :
- 13507540
- Database :
- OpenAIRE
- Journal :
- Current Opinion in Neurology, Current Opinion in Neurology, Lippincott, Williams & Wilkins, 2020, 33 (4), pp.413-421. ⟨10.1097/WCO.0000000000000833⟩, Current Opinion in Neurology, 2020, 33 (4), pp.413-421. ⟨10.1097/WCO.0000000000000833⟩, Curr Opin Neurol
- Accession number :
- edsair.doi.dedup.....6cbf5ab1c6e2dbddf1cd87b68ba97692